Certain urine biomarkers related to inflammation and oxidant stress correlate with established predictors of cardiovascular disease and may help assess risk for heart problems among HIV-positive people on antiretroviral therapy according to a small pilot study presented at the XVII International AIDS Conference in Mexico City.
Cardiovascular disease (CVD) among HIV-positive patients is a growing concern as people with HIV are living longer. Several studies have found an association between heart attacks and antiretroviral therapy, and the large SMART treatment interruption trial showed that ongoing HIV replication itself appears to increase the risk of serious heart, liver, and kidney disease.
http://www.aidsmap.org/en/news/5A879218-2847-4530-9EFF-03FCA67E7117.asp